#### **PCT**

### WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:			
A61K 31/19, 31/215, 31/34, 31/44	A3	(11) International Publication Number:	WO 97/24116
, ===, ===,		(43) International Publication Date:	10 July 1997 (10.07.97)
(21) International Application Number: PCT/U	J <b>S9</b> 6/205	11 (81) Designated States: AL, AM, AT, A	II AZ RA RR RC DD
(22) International Filing Date: 16 December 1996	(16.12.9	BY CA CH CN CH CZ DE	DK, EE, ES, FI, GB, GE, GR, KZ, LC, LK, LR, LS
(30) Priority Data: 08/580,553 29 December 1995 (29.12.	.95) [	PT. RO, RU, SD, SE, SG, SI, SUG, UZ, VN, ARIPO patent (KI Eurasian patent (AM, AZ, BY, K European patent (AT, BE, CH, I	SK, TJ, TM, TR, TT, UA, E, LS, MW, SD, SZ, UG), G, KZ, MD, RU, TJ, TM)

# (71) Applicant: ALLERGAN [US/US]: 8301 Mars Drive, Waco, TX 76712 (US).

- (72) Inventors: TENG, Min; 2 Dove Street, Aliso Vicjo, CA 92656 (US). DUONG, Tien, T.; Apartment 15C, 13 Bearpaw, Irvine, CA 92714 (US). CHANDRARATNA, Roshantha, A.; 25841 Empresa, Mission Viejo, CA 92691 (US).
- (74) Agents: BARAN, Robert, J. et al.; Allergan, Inc., 2525 Dupont Drive, T-2,2-E, P.O. Box 19534, Irvine, CA 92623-9534 (US).

#### Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ,

CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
13 November 1997 (13.11.97)

(54) Title: METHODS OF TREATMENT WITH COMPOUNDS HAVING RAR. RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY

#### (57) Abstract

Retinoid compounds which act specifically or selectively on  $RAR_{\alpha}$  receptor subtypes in preference over  $RAR_{\beta}$  and  $RAR_{\gamma}$  receptor subtypes, possess desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenicity.

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

		•			
AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NI.	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belanus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	\$G	Singapore
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	Li	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ	Swaziland
CS	Czechoslovakia	LT	Lithuania	TD	Chad
CZ	Czech Republic	LU	Luxemboure	TG	Togo
DE	Germany	L.V	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinidad and Tobago
EE	Estonia	MD	Republic of Moldova	ÜA	Ukraine
ES	Spain	MG	Madagascar	UG	Uganda
FI	Finland	ML	Mali	US	United States of America
FR	France	MN	Mongolia	UZ	Uzhekistan

Interr al Application No

			PCT/US	96/20511
IPC 6	SIFICATION OF SUBJECT MATTER A61K31/19 A61K31/215 A61K	31/34	A61K31/44	
According	to International Patent Classification (IPC) or to both national	l classification ar	nd IPC	
	S SEARCHED			
Minimum IPC 6	documentation searched (classification system followed by cla $A61K$	ssification symbo	ols)	
Document	ation searched other than minimum documentation to the exter	nt that such docu	ments are included in the field	s searched
Electronic	data base consulted during the international search (name of d	ata base and, who	ere practical, search terms use	d)
C. DOCUN	MENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of	the relevant pass	sages .	Relevant to claim No.
X	WO 93 03713 A (SALK INST FOR E STUDI) 4 March 1993	BIOLOGICA	<u>.</u>	1-4, 6-12,
	see page 9, line 4 - line 31;	claims 1	-15	14-22
		-/		
				-
Ì	•			
	er documents are listed in the continuation of box C.	X Pat	ent family members are listed	in annex.
	gories of cited documents :	"T" later do	cument published after the uni	emational filing date
COUNTRIC	nt defining the general state of the art which is not red to be of particular relevance ocument but published on or after the international	or briot	understand the principle or the	III IDE souleesteen heet
L" documen	it which may throw doubte on enjoyity elaim(e) on	-atmict	nt of particular relevance; the be considered novel or cannot an inventive step when the do	De considered to
citation  Of document	t due to establish the publication date of another or other special reason (as specified)  at referring to an oral disclosure, use, exhibition or	"Y" docume cannot	nt of particular relevance; the	daimed invention
P* documen	cans  It published prior to the international filing date but  In the priority date claimed	ments, in the a	nt is combination being obvious.  It is combination being obvious.	ore other such docu- us to a person skilled
	ctual completion of the international search		nt member of the same patent mailing of the international se	
13	May 1997		09.97	
ame and ma	illing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authoriz	ed officer	
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Se	egert. K	

1

Intern. usi Application No PCT/US 96/20511

CIC	1 DOCUMENTS CONSTRUCTION TO BE DESCRIPTION.	PC1/03 90/20511
Category *	tion) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Υ	CHEMICAL ABSTRACTS, vol. 121, no. 9,	1-4, 6-12,
	Columbus, Ohio, US; abstract no. 108128d, XP002030814	14-22
	see abstract & YU, BAOXIN ET AL: "Synthesis of p-substituted benzoylaminobenzoic acid (methyl esters) and its differentiation	
	induction activities of human promyelocytic leukemia cells HL-60* HUAXI YIKE DAXUE XUEBAO, vol. 25, no. 1, 1994,	
	pages 30-34,	
Y	DATABASE WPI Section Ch, Week 9416 Derwent Publications Ltd., London, GB; Class B05, AN 94-128759 XP002030803 & JP 06 072 866 A (CHUGOKU IGAKUKAGAKUIN YAKUBUTSU KENKYUSH), 15 March 1994	1-4, 6-12, 14-22
Y	see abstract EP 0 514 269 A (CIRD GALDERMA) 19 November	1.4
	see page 3, line 3 - page 3, line 9; claims 1-21 especially claim 16, ex. 15	1-4, 6-12, 14-22
Y	EP 0 350 846 A (HOFFMANN LA ROCHE) 17 January 1990	1-4, 6-12, 14-22
	see page 5, line 43 - page 6, line 35; claims 1-18	
Υ	US 5 420 145 A (SHUDO KOICHI) 30 May 1995	1-4, 6-12, 14-22
	see column 3, line 65 - column 4, line 29; claims 1-4	4.1 444
Y	EP 0 170 105 A (SHUDO KOICHI ;SUMITOMO PHARMA (JP); YOSHITOMI PHARMACEUTICAL (JP)) 5 February 1986 see claims 1-11	1-4, 6-12, 14-22
P,Y	WO 96 32101 A (TAIHO PHARMACEUTICAL CO LTD; SHIBATA JIRO (JP); WIERZBA KONSTANTY) 17 October 1996 see abstract	1-4, 6-12, 14-22
	-/	

Inten nal Application No
PCT/US 96/20511

C.(Continu	DOCUMENTS CONSIDERED TO BE RELEVANT	S 96/20511		
Category *	Citation of document, with indication, where appropriate, of the relevant passages  Relevant to claim No.			
Y	KAGECHIKA H ET AL: "RETINOBENZOIC ACIDS STRUCTURE-ACTIVITY RELATIONSHIPS OF AROMATIC AMIDES WITH RETINOIDAL ACTIVITY" JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, no. 11, November 1988, pages 2182-2192, XP000608417 see tables I-VI see page 2187, left-hand column, last paragraph - page 2188, left-hand column	1-4, 6-12, 14-22		
Р, Ұ	MIN TENG ET AL: "Identification of a Retinoic Acid Receptor alpha Subtype Specific Agonist" J. MED. CHEM., vol. 39, no. 16, 2 August 1996, pages 3035-3038, XP000652115 see the whole document	1-4, 6-12, 14-22		

Inte fional application No.

PCT/US 96/20511

Box i	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2.	Claims Nos.:
	because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This Inte	emational Searching Authority found multiple inventions in this international application, as follows:
Se	e annex.
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
, [	As subspaces of the manifest and statement and the
" <u> </u>	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. X	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
	1-4,6-12, 14-22 (partially)
Remark	con Protest  The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

### FURTHER INFORMATION CONTINUED FROM PCT/ISAL 10

- 1. The use of a RAR alpha selective agonist for the prevention/treatment of acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas, head and neck carcinomas (respective portions of Claims 1- 4, 6-12, 14 22)
- 2. The use of a RAR alpha selective agonist for the prevention/treatment of proliferative vitreoretinopathy (PVR), age related macular degeneration (AMD), diseases of the eye, retinal detachment, dry eye, other corneopathies (respective portions of Claims 1 22)
- 3. The use of a RAR alpha selective agonist for the prevention/treatment of actinic keratoses, arsenic keratoses, inflammatory and non-inflammatory acne. psoriasis, ichtyoses, eczema, atopic dermatitis, Darriers disease, lichen planus, skin pigmentation, age and photo damage to the skin, premalignant and malignant hyperproliferative diseases, Kaposi's sarcoma (respective portions of Claims 1, 2, 4 13, 15- 22)
- 4. The use of a RAR alpha selective agonist for the prevention/treatment of cardiovascular diseases (respective portions of Claims 1, 2, 4 13, 15-22)
- 5. The use of a RAR alpha selective agonist for the prevention/treatment of dyslipidemias (respective portions of Claims 1, 2, 4 13, 15- 22)
- 6. The use of a RAR alpha selective agonist for the prevention of post-angioplasty restenosis (respective portions of Claims 1, 2, 4 13, 15- 22)

#### FURTHER INFORMATION CONTINUED FROM PCT/ISAL 10

- 7. The use of a RAR alpha selective agonist for the prevention/treatment of diseases associated with human papilloma virus (HPV) (respective portions of Claims 1, 2, 4 13, 15-22)
- 8. The use of a RAR alpha selective agonist for the for the prevention/treatment of inflammatory diseases (respective portions of Claims 1, 2, 4 13, 15- 22)
- 9. The use of a RAR alpha selective agonist for the prevention/treatment of neurodegenerative diseases (respective portions of Claims 1, 2, 4 13, 15- 22)
- 10. The use of a RAR alpha selective agonist for the prevention/treatment of improper pituitary function (respective portions of Claims 1, 2, 4 13, 15-22)
- 11. The use of a RAR alpha selective agonist for the prevention/treatment of insufficient hair growth (respective portions of Claims 1, 2, 4 13, 15-22)
- 12. The use of a RAR alpha selective agonist for the prevention/treatment of diseases associated with the immune system (respective portions of Claims 1, 2, 4 13, 15- 22)
- 13. The use of a RAR alpha selective agonist for wound healing (respective portions of Claims 1, 2, 4 13, 15-22)

The search has been limited to the subject-matter of item 1.

information on patent family members

Inten nal Application No
PCT/US 96/20511

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9303713 A	04-03-93	AU 2516092 A CA 2114936 A EP 0600028 A JP 7505607 T US 5668175 A	16-03-93 04-03-93 08-06-94 22-06-95 16-09-97
EP 0514269 A	19-11-92	FR 2676440 A AT 129698 T AU 650972 B AU 1627392 A CA 2068696 A DE 69205725 D DE 69205725 T ES 2080458 T JP 5221951 A	20-11-92 15-11-95 07-07-94 19-11-92 16-11-92 07-12-95 30-05-96 01-02-96 31-08-93
EP 0350846 A	17-01-90	AT 128974 T AU 626881 B AU 3709789 A CA 1319364 A DE 58909463 D ES 2078905 T FI 96204 B IE 70450 B IL 90912 A JP 2053684 C JP 2076862 A JP 7086094 B PT 91158 B US 5420273 A US 5037825 A US 5164387 A US 5300522 A MX 16751 A	15-10-95 13-08-92 18-01-90 22-06-93 16-11-95 01-01-96 15-02-96 27-11-96 25-01-94 23-05-96 16-03-90 20-09-95 01-03-95 30-05-95 06-08-91 17-11-92 05-04-94 01-10-93
US 5420145 A	30-05-95	EP 0617020 A	28-09-94
EP 0170105 A	05-02-86	JP 1764534 C JP 4058458 B JP 61022047 A	28-05-93 17-09-92 30-01-86

Information on patent family members

Intern al Application No
PCT/US 96/20511

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0170105 A		JP 1764542 C JP 4058459 B JP 61076440 A US 4703110 A	28-05-93 17-09-92 18-04-86 27-10-87
WO 9632101 A	17-10-96	AU 5287596 A CA 2191850 A EP 0768084 A	30-10-96 17-10-96 16-04-97